Quick Hits

The availability of highly efficacious and tolerable all-oral direct acting antiviral (DAA) regimens for the treatment of chronic hepatitis C virus (HCV) infection in 2014 was met with a mix of joy and relief among both HCV providers and chronically infected patients. Finally we could do away with the low cure rates and toxicities associated […]

Quick Hits

The prevalence of hepatitis C (HCV) in dialysis patients is higher than that of the general population, ranging from 1.8 to 8 percent in developed countries, with much higher rates in the developing world. Its prevalence correlates with the number of patient-years on dialysis. HCVinfected patients on maintenance dialysis experience increased mortality compared to uninfected […]